HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on X4 Pharmaceuticals (NASDAQ:XFOR) and raises the price target from $3 to $5.
April 30, 2024 | 10:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on X4 Pharmaceuticals and increases the price target from $3 to $5.
The upgrade in the price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the company's future performance, potentially leading to increased investor confidence and a rise in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100